Create your own free news widgets.

Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, announced that the Company is exhibiting the next generation of its Clarity System at the 23rd Annual Canadian Association of Radiation Oncology (CARO) being held in Quebec City, Canada.

Minnow Medical, Inc., a developer of innovative products to treat artery disease, announced that positive clinical trial results using the Company's Guided Reshaping Technology (GRTT) to treat peripheral artery disease (PAD) were presented last week at the TCT 2009 Conference in San Francisco. James R. Margolis M.D.

Journal of Natural Products, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Journal of Natural Products)

Blue Cross Blue Shield of Michigan today announced a new Medicare Advantage PPO product that for many Michigan seniors provides benefits at lower premiums than Original Medicare coupled with Part D drug plans and supplementary coverage.

BRUSSELS (Reuters) - The European Union's food safety watchdog delivered a long-awaited opinion on Thursday to the EU executive arm that will help determine whether food producers' health claims about their products are backed up by science.

Today, eleven public health and consumer advocacy organizations filed a friend of the court (amicus) brief asking a federal court to reject a lawsuit by R.J. Reynolds, Lorillard and other tobacco companies that seeks to block key provisions of the new federal law regulating tobacco products. The immediate issue before the court is the industry's challenge of a provision that requires FDA approval before tobacco companies can make claims about 'modified risk tobacco products.

Flexible plastic solar cells that can be printed like money, carbon fibres so thin they can be spun into yarns and a raft of new biomedical products to combating illness and injury are just some of the research breakthroughs being developed by the new CSIRO National Research Flagship for Future Manufacturing just launched. The Flagship - a $A36.

VeriChip Corporation ('VeriChip') (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGNT chemistry platform can be applied to the development of selective binding products, announced that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip.

The Food and Drug Administration today began collecting millions in fees from the nation's tobacco companies to help fund the agency's newly granted authority to regulate the industry. The user fees, which will be collected quarterly, are based on each company's share of the U.S. tobacco market. The FDA will collect about $23 million for fiscal 2009. That will rise to $235 million in 2010 and grow to $712 million by 2019. The FDA would not disclose the assessments for specific companies. Stifel, Nicolaus & Co. analyst Christopher Growe said in a note to investors that Henrico County-based Altria Group Inc., owner of market-leading Philip Morris USA, would be responsible for about 50 percent of the fees. FDA spokeswoman Kathleen Quinn said the fees will be used to fund the Center for Tobacco Products, the agency's group tasked with regulating tobacco. The fees will pay for staffing, offices, systems that will be used to register products and outside contractors.

MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, provided a clinical development update for Perceiva, the company's proprietary ocular sirolimus product. The company has completed patient enrollment in four ongoing Phase 2 clinical trials of Perceiva and plans to announce data from these studies in the first half of 2010. All four studies are being conducted at investigational sites in the United States.